Adverse drug reactions: classification, susceptibility and reporting

Area of Science:

• Pharmacology and Toxicology
• Patient Safety
• Clinical Pharmacy

Background:

• Adverse drug reactions (ADRs) represent a significant global health challenge, contributing to morbidity and mortality.
• Traditional classification systems (Type A and Type B) are insufficient to categorize all ADRs.
• Emerging categories (Type C, D, E) address reactions beyond predictable or idiosyncratic responses.

Purpose of the Study:

• To review and expand upon the classification of adverse drug reactions.
• To highlight factors influencing susceptibility to ADRs.
• To emphasize the role of healthcare professionals in ADR monitoring and reporting.

Main Methods:

• Literature review of ADR classification systems.
• Analysis of factors contributing to ADRs.
• Discussion of clinical implications for healthcare professionals.

Main Results:

• ADRs are classified into Type A (predictable), Type B (idiosyncratic), and extended categories (C, D, E).
• Susceptibility to ADRs is multifactorial, influenced by patient demographics (age, gender, ethnicity), health status (disease states, pregnancy), and medication regimens (polypharmacy).
• Healthcare professionals play a vital role in identifying, managing, and reporting ADRs.

Conclusions:

• A comprehensive understanding of ADR classification and influencing factors is essential for effective patient care.
• Vigilance in monitoring and reporting ADRs, such as through the Yellow Card Scheme, is critical for drug safety.
• Optimizing medicine use through collaboration between healthcare providers and patients can mitigate ADR risks.